-
公开(公告)号:JP2771328B2
公开(公告)日:1998-07-02
申请号:JP50793890
申请日:1990-05-25
申请人: ERBA CARLO SPA
发明人: DOSUTEERU FUIRITSUPU , PEBARETSURO PAORO , HEIDENPERUGIRU FURANKO , BARASHI MARIO , BONSHINYORI ARUBERUTO , RONKUTSUCHI ROMEO
IPC分类号: C07C237/06 , A61K31/16 , A61K31/33 , A61K31/34 , A61K31/341 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61P25/00 , A61P25/08 , A61P25/20 , A61P25/24 , A61P25/26 , C07C231/02 , C07C231/10 , C07C323/63 , C07D213/30 , C07D307/42 , C07D307/58 , C07D333/16 , C07D333/32
-
公开(公告)号:JPH07252291A
公开(公告)日:1995-10-03
申请号:JP29649994
申请日:1994-11-30
申请人: ERBA CARLO SPA
IPC分类号: C12P29/00 , C07H1/06 , C07H15/24 , C07H15/252
-
公开(公告)号:JPH06228152A
公开(公告)日:1994-08-16
申请号:JP30422193
申请日:1993-12-03
申请人: ERBA CARLO SPA
IPC分类号: A61K31/545 , A61K31/546 , A61P29/00 , A61P43/00 , C07D501/00 , C07D501/16 , C07D501/20 , C07D501/38 , C07D501/59 , C07D519/00 , C07D519/06
-
公开(公告)号:JPH05132482A
公开(公告)日:1993-05-28
申请号:JP10491092
申请日:1992-04-23
申请人: ERBA CARLO SPA
发明人: PAORO KOTSUTSUI , ANTONIO PITSURAN , MAURITSUIO PURICHI , PATORICHIA SARUBATEI , ANJIERO DANIERE BORUPI
IPC分类号: A61K31/415 , A61K31/405 , A61K31/4178 , A61P7/02 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/02 , A61P15/00 , A61P25/06 , C07D209/04 , C07D233/58 , C07D403/10 , C07D521/00
-
公开(公告)号:JPH04346977A
公开(公告)日:1992-12-02
申请号:JP2400792
申请日:1992-02-10
申请人: ERBA CARLO SPA
发明人: PAORO KOTSUTSUI , ANTONIO JIYORUDAANI , ARUSENIA ROTSUSHI , PATORIICHIYA SARUBAATEI , KORAADO FUERUTEI
IPC分类号: A61K31/415 , A61K31/353 , A61K31/366 , A61K31/4178 , A61K31/695 , A61P7/02 , A61P9/08 , A61P9/10 , A61P11/00 , A61P11/08 , A61P13/02 , A61P15/00 , A61P25/04 , A61P43/00 , C07D233/54 , C07D233/61 , C07D405/06 , C07D409/14 , C07D521/00 , C07F7/08
-
公开(公告)号:JPH04283515A
公开(公告)日:1992-10-08
申请号:JP29747691
申请日:1991-11-13
申请人: ERBA CARLO SPA
IPC分类号: A61K31/185 , A61K39/395 , A61K45/06 , A61P9/08 , A61P9/10 , A61P11/00 , A61P29/00 , A61P31/04 , A61P33/02 , A61P37/00 , A61P37/06 , A61P37/08 , A61P43/00
摘要: PURPOSE: To prevent or treat diseases in which TNF-α plays a detrimental role, by administering suramin or its salt. CONSTITUTION: 8,8'-(Carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3, 1-phenylene)carbonylimino))bis-1,3,5-naphthalenesulfonic acid (suramin) or its pharmaceutically permissible salt is used as a preventive and/or therapeutic agent for a disease state in which TNF-α plays a detrimental role. In treating the disease, preferably an active substance selected from γ-globulin, immunoglobulin, monoclonal antibody, antibiotic and antimicrobial agent is simultaneously, separately or successively used. Diseases such as cachexia, septic shock, AIDS, chronic rheumatoid arthritis, disease caused by host reaction to transplant, brain malaria, myocardial ischemia, reperfusion, bacterial granuloma, etc.
-
公开(公告)号:JPH0353885A
公开(公告)日:1991-03-07
申请号:JP18781190
申请日:1990-07-16
申请人: ERBA CARLO SPA
-
公开(公告)号:JPH0338595A
公开(公告)日:1991-02-19
申请号:JP16655690
申请日:1990-06-25
申请人: ERBA CARLO SPA
IPC分类号: A61K31/70 , A61K31/7028 , A61K31/7034 , A61K31/704 , A61P31/04 , C07H15/252
-
公开(公告)号:JPH02157225A
公开(公告)日:1990-06-18
申请号:JP27144189
申请日:1989-10-18
申请人: ERBA CARLO SPA
IPC分类号: A61K31/545 , A61P31/04
摘要: PURPOSE: To obtain a drug composition containing a penem derivative FCE 22101 and ceftizoxime, exhibiting synergistic antibacterial action and useful for the treatment of the infection of respiratory system, urinary duct, etc. CONSTITUTION: The objective composition is produced by using (5R,6S)-2- carbamoyloxymethyl-6-([(1R)-hydroxyethyl]-penem-2-carboxylic acid (FCE 22101) or its salt or ester and 7-[2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3- cephem-4-carboxylic acid (ceftizoxime) or its salt or ester as active components and forming to a drug preparation by conventional method. The weight ratio of FCE 22020/ceftzoxime is 10:1 to 1:3 in terms of pure antibiotic equivalent. The daily administration dose of the composition is 1-3g for adult (70kg body weight).
-
公开(公告)号:JPH024718A
公开(公告)日:1990-01-09
申请号:JP6060589
申请日:1989-03-13
申请人: ERBA CARLO SPA
摘要: PURPOSE: To obtain a matrix comprising a drug, capable of keeping the release of the drug at a constant rate and nonuniformly distributed therein by immersing a specific cross-linked siloxane matrix in a solution containing the drug dissolved in a solvent, swelling the matrix and then drying the swollen matrix. CONSTITUTION: This siloxane matrix nonuniform in internal distribution of a drug is prepared by mixing an uncross-linked siloxane base polymer, preferably a polymer having methylvinyl polysiloxane units with a curing agent (e.g. a polymer having the methylvinyl polysiloxane units) and a catalyst, as necessary, a filter and/or an additive, arranging the resultant mixture in a metallic mold, cross-linking the mixture for preferably 20-60hr, preparing a siloxane matrix, immersing the prepared siloxane matrix in a solution containing the drug (e.g. methylhydroxyprogesterone acetate) dissolved in a low-boiling solvent such as methylene chloride or cyclohexane, swelling the matrix and then drying the swollen matrix.
-
-
-
-
-
-
-
-
-